Do Chomhpháirtí Iontaofa le haghaidh Athfhás Gruaige

Mar sin, ar cheart dom a bheith buartha faoi chaillteanas gruaige?

Léigh tuilleadh

An bhféadfá achoimre chruinn a thabhairt ar na rudaí a ndéanann gairm na triheolaíochta sainfheidhmiú orthu?

Léigh tuilleadh

Cad a cheapann tú faoi theiripe chomhcheangailte le haghaidh caillteanas gruaige?

Léigh tuilleadh

Cad iad cuid de na buntáistí a bhaineann le teiripe léasair ar leibhéal íseal?

Léigh tuilleadh

Cén fáth a molfá HairMax go pearsanta d’othar?

Léigh tuilleadh

Cad iad na gnéithe sonracha de HairMax a sheasann amach duit mar thriceolaí?

Léigh tuilleadh

Conas a dtugann tú aghaidh ar amhras faoi HairMax?

Léigh tuilleadh

An n-oibríonn Teiripe Léasair HairMax i ndáiríre?

Léigh tuilleadh

An Ba Chóir Duit HairMax a Áireamh i do Chóireáil Caillteanas Gruaige?

Léigh tuilleadh

An Féidir Leat HairMax a Úsáid Ró-Mhinic agus An bhfuil Éifeachtaí Taobhacha Aonair air?

Léigh tuilleadh

Gléas HairMax i gcoinne Clinic Athfhás Gruaige Laser: Cad é an Difríocht?

Léigh tuilleadh

Cé chomh fada a thógann sé chun torthaí a fheiceáil ó HairMax?

Léigh tuilleadh

An Féidir HairMax a Úsáid Tar Éis Nósanna Imeallach Glandála Gruaige?

Léigh tuilleadh

An Féidir HairMax a Úsáid le Cóireálacha Easaontais Gruaige Eile?

Léigh tuilleadh

An bhfuil Staidéir Eolaíocha ann a Thacaíonn le héifeachtúlacht HairMax?

Léigh tuilleadh

HairMax Lasers i gcoinne LEDs Iomaíoch: Cad é an Difríocht?

Léigh tuilleadh

Fiosraigh an Eolaíocht

Chuir Hairmax® maoiniú agus thosaigh sé an taighde eolaíoch ar theiripe léasair leibhéal íseal don chailliúint gruaige.

Ceannaigh Anois

Androgenetic alopecia (male pattern hair loss) in the United States: what treatments should primary care providers recommend?

Overview: AGA affects up to 96% of Caucasian men. This review recommends minoxidil, finasteride, and FDA-cleared HairMax LaserComb® for non-responders.

Key Findings:

Topical minoxidil and finasteride are first-line treatments.
HairMax LaserComb® is recommended for patients who do not respond to first-line modalities.

Source: PubMed ID: 24170634

Effects of the Lexington LaserComb on hair regrowth in the C3H/HeJ mouse model of alopecia areata

Overview: 24-week, randomized, double-blind, sham device-controlled trial of LLLT for AGA. LLLT-treated scalp showed greater hair coverage and improvement.

Key Findings:

LLLT-treated scalp showed significantly greater hair coverage and improvement in hair thickness, count, and coverage compared to sham.
No serious adverse events were observed.

Source: PubMed ID: 29957664

Efficacy and safety of a low-level laser device in the treatment of male and female pattern hair loss: a multicenter, randomized, sham device-controlled, double-blind study

Overview: Multicenter, randomized, sham device-controlled, double-blind study of HairMax LaserComb® for increasing terminal hair density in men and women.

Key Findings:

LaserComb treatment significantly increased terminal hair density compared to sham.
No serious adverse events; improvement was independent of age, sex, or device model.

Source: PubMed ID: 24474647

Efficacy of fractional lasers in treating alopecia: a literature review

Overview: Review of fractional lasers and LLLT devices (HairMax LaserComb®) for hair regrowth in alopecia.

Key Findings:

Fractional lasers may promote hair growth via wound healing; LLLT devices are safe and effective for hair loss.
More randomized controlled trials are needed to establish optimal parameters and intervals.

Source: PubMed ID: 28812164